Crowdonomics
All companies
PherDal Fertility Science, Inc. logo

PherDal Fertility Science, Inc.

Operating

Healthcare · Technology · Dixon, IL · Founded 2016

Building families through science

Post-money valuation ⓘ
$14.6M
As of Dec 2022 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$387,017
Across 1 round since 2022
Latest share price
$1.87
Reg CF · Common Stock · Jul 2022 offering price

Financials

FY2020–FY2024 · from SEC filings · hover any figure for its source
$0
$3K
2020
$0
2021
$0
−$186K
2022
$0
−$253K
2023
$92K
−$275K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020 reviewed
FY2021 reviewed
FY2022 unaudited
FY2023
FY2024
Income statement
Revenue
$0
$0
$0
$0
$91,850
Cost of goods sold
$0
$0
$0
$0
$22,420
Gross margin
—
—
—
—
76%
Net income
$2,511
$0
-$186,418
-$253,435
-$275,379
Taxes paid
$0
$0
$1,048
$3,067
$7,006
Balance sheet
Cash
$6,470
$0
$167,105
$316,846
$16,830
Accounts receivable
$0
$0
$134,366
$0
$0
Total assets
$6,470
$0
$419,690
$519,162
$416,891
Short-term debt
$5,368
$0
$0
$320,000
$500,000
Long-term debt
$0
$0
$0
$0
$0
Total liabilities
$5,368
$0
$0
$320,000
$500,000
Other
Headcount
—
10
1
1
10

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$14.0M
pre-money
Reg CF · Common · Jul 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Cap table

Share counts as of Dec 31, 2022
ClassOutstandingVotes / shareShare of totalLast price
Common Stock7,368,085—100.0%$1.87Jul 2022

Shares outstanding over timein today's share terms

7.4M3.7M0
Apr 2022Dec 2022
Common StockRound opened

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $387K / $1.1MInvestors 423Post-money $14.6M

Team

12 people
Dr. Jennifer Hintzsche, Ph.D.Founder
Chief Executive Officer

Dr. Jenn is a wife, mother, innovator, and passionate advocate for women’s health. Hintzsche was Northern Illinois University’s first recipient of a doctoral degree in bioinformatics (a field of study that combines computer science and biology) in 2014 after obtaining a Master's Degree in the same subject. She earned her BA in Biochemistry from Augustana College. She is the author of over two-dozen peer-reviewed scientific articles and her work has been cited nearly 500 times in respected science journals for her clinical expertise. Dr. Jenn was diagnosed with unexplained infertility in 2017 and was told expensive fertility options were her only chance at conceiving. Hintzsche and husband Ryan invented and conceived their daughter using their patent-pending PherDal kit. PherDal is the only sterile at-home insemination kit that has already helped over a dozen women conceive. PherDal is located in Dixon, IL and is registered with the FDA as an over the counter medical device.

Jennifer Westphal
CEO
Dr. Rhonda Alexander
Chief Regulatory Officer

Dr. Rhonda Alexander is a global entrepreneur, speaker, coach, and author. She is the founder of IUVO Consulting, LLC, an international regulatory-compliance consulting firm, and E2 Entrepreneur & Executive Coaching, LLC, a firm dedicated to facilitating the growth and development of entrepreneurs and leaders. In addition to authoring three books: EntrHERpreneur, Your Life’s Calling, and Side-Hustle or Sustainable, Dr. Rhonda has worked with organizations and professionals around the world. As a result, she has garnered more than 25 years of unique experiences that make her a creative organizational strategist, as well as an inspired, compassionate, and driven speaker and coach. Dr. Rhonda is the mother of Maiyah, an amazing young woman, who is the joy and pride of her life.

Kristin Perez
Chief Marketing Officer

Kristin Perez is the owner of Unplug Marketing which first established PherDal's social media presence in late 2021. Kristin enjoys using her social media skills to contribute to the success of small businesses. She has been in the marketing industry, and specifically social media for over 15 years. In her free time, Kristin likes to hike and spend time with her husband and two-year-old daughter.

Makeva Phelps
Chief Operations Officer

With over 25 years of various pharmacy, account management, audit and operations experience, Makeva collaborates with executive leadership, internal and external clients to define long-term goals and identify ways to support the clients mission. Makeva's primary focus is process improvement, efficiency, and training and development. Makeva is a strategic, innovative, and results driven leader committed to partnering with business stakeholders to improve performance and drive results. Makeva is dedicated to enhancing customer and client engagement and fostering a culture that supports the overall business objectives. Prior to joining the Pherdal Executive board, Makeva held roles as a Client Experience Manager, Operations Manager, and Benefits Auditor. Makeva holds a B.S. Business Forensics from Franklin University and B.A. Business Administration from University of Phoenix. *Currently on extended bereavement leave, return date TBD*

Matthew Croll
Chief Financial Officer

Matt Croll has nearly 30 years of finance experience including more than 15 years a CFO. He has worked with a variety of companies in manufacturing, distribution, consumer products, agriculture, and professional services. Matt brings a multi-faceted view to business opportunities and a strong analytical perspective to business decisions. He founded Vector CFO in 2014. Vector CFO delivers fractional CFO services to companies that have needs best served by a seasoned CFO but who lack the scale to require a full-time CFO. During his career, Matt has evaluated dozens of M&A opportunities and executed more than 25 acquisitions or divestitures of businesses. He has also served as CFO during periods of rapid growth within companies. Matt received his BS in Accountancy from the University of Illinois and his MBA from Northwestern University. He is a registered CPA. Matt resides in Naperville, IL with his wife and two daughters. He enjoys staying active and participating in various sports in his spare time.

Ryan Westphal
Chief Engineer & Secretary of the Board

Ryan Westphal has 15+ years of engineering experience in the automotive and aerospace industries. Over the last 10+ years, he has been focused on the development of emissions devices such as heat exchangers, rotary electric valves and actuators. Ryan currently brings his breadth of experience and leadership in new product launch to a team of engineers, designers and technicians working with the major commercial vehicle and passenger car OEM’s in North America. Ryan received his Bachelor of Science in Mechanical Engineering from Northern Illinois University in 2008 and resides in Dixon, IL with his wife Jenn and children Lois and Zack. In his free time he is an avid Chicago Bears fan, enjoys tinkering on his car and advancing his 3D printing skills.

David Hintzsche
Chairman of the Board

David Hintzsche was part of the team who grew a family-owned agri-business into a company. For 42 years, he had a successful career with many titles at Hintzsche Fertilizer, Inc., in Illinois. The business grew with over 150 million in sales, 225 employees at 15 ag retail locations, and many contract pork production sites in northern Illinois and eastern Iowa. He is also the grandfather of the first PherDal baby. David started working at Hintzsche Fertilizer, Inc. as a Second-shift Feed Mill Operator while attending Waubonsee Community College. After two years of college, he became a custom operator, then Troxel Plant Manager. In 1979, David became the Agronomy Division Manager for 11 years, moving his way up in the organization to the General Manager. In 1995, he became the President and Chief Executive Officer. He led the family owned business for 19 years before it was sold in 2014. David was on several board affiliations including: Hintzsche Companies from 1990 to 2014, Premier Crop Systems from 2000 to 2007 and joined the board again in 2014. He was also on the board at DeKalb County Economic Development Corporation from 2005 to 2013, and United Suppliers and Agricultural Retailers Associations from 2011 to 2014. He was a Vistage (CEO peer group) member from 2002 to 2014 and recently joined the Willard Agri-Service Board of Directors at the beginning 2015.

Dr. Steven R. Lindheim, M.D., M.M.M.
Medical Advisor

Dr. Lindheim is a Professor of Obstetrics and Gynecology at both Wright State University, Boonshoft School of Medicine in Dayton, Ohio and the University of Central Florida in Orlando, Florida, as well as Visiting Professor of Shanghai Jiao Tong University School of Medicine in Shanghai, China. He graduated from Temple School of Medicine and was a resident at Pennsylvania Hospital in Philadelphia. Dr. Lindheim completed a fellowship in Reproductive Endocrinology and Infertility at the University of Southern California, his Masters in Medical Management from Tulane University, School of Public Health and Tropical Medicine, and is currently Board Certified in both Ob/Gyn and Reproductive Endocrinology and Infertility. He previously served on as the Board of Directors for ASRM and is Past President for the Society of Reproductive Surgeons. Dr. Lindheim has a major interest in In vitro fertilization, oocyte donation, embryo donation and surrogacy. He is a well-recognized expert in the field of minimally invasive reproductive surgery and has over 250 scientific publications, and book chapters and is Associate Editor for Fertility Sterility. His research focuses upon embryo implantation, minimally invasive reproductive surgery, and Polycystic Ovarian Syndrome (PCOS).

Show 3 more people
Tessa Mills
Advisor, Brain-based coach + fertility doula for women

Hey friend! I’m Tessa Mills, the second PherDal momma as well as a brain-based coach, fertility doula and bodyworker. I’ll help you understand how your mind-body machine works, use intuitive questioning to help you uncover your own answers and teach you self-care tools that fuel your journey to creating the life you desire. When I say “self-care”, I’m not talking about expensive spa treatments or bubble baths (although those feel pretty damn good once in awhile!). I’m talking about self-care tools that help you 1) become aware of the thoughts making you feel like shit and 2) Re-wire your thinking to calm your nervous system and fuel the most evolved parts of your brain (i.e. So you can So whether you want to take charge of your reproductive health and fertility, discover the courage to leave a toxic relationship, or simply create a soul-affirming life that has you jumping out of bed before the sun comes up, I’ll guide you there with fun, effective and science-based tools and strategies.

Dr. Karla Loken DO OBGYN FACOOG
Advisor

It is an exciting time to be a physician in Industry. I am always learning, and cherish the opportunity to collaborate with talented people in all areas of medical affairs, regulatory, research, and medical education, making a global impact on women’s health! I of course miss and always will miss the privilege to be 1:1 with patients. I was so lucky to have opportunities and experiences as an OB/GYN in private practice /MIS, in academics, and as a hospitalist. Experienced in: Medical Device Development and Strategy, Marketing and VOC FDA and EU MDA experience in CER, CEP and PFCP and COPA Medical Affairs, Regulatory, Payors , Pharmacovigilance, Medical Education, Device Proctoring, and Medical Marketing and HEOR, PMRP, Good Clinical Practice. Clinical Trail Oversight and Onboarding as well as protocol development. VEEVA, Medra, AGILE, Scrum, and Oracle & Teams experience. Individual career transition coaching. Cross-functional team player. Consulting on non-clinical career transition for physicians. Patient Journey, Payer Ad Board Development. Evidence Generation, GCP, Clinical Research Oversight, Onboarding, and Protocol development. ACOOG gov affairs committee -post. PESC- Graduate Education Review committee - post. Girls Experiencing Medical Science mentor ( Gems) girl-scout camp.

Kelly Hintzsche
Advisor

My law practice is focused in the areas of business and corporate transactions; estate planning and administration; and residential and commercial real estate. I have advised corporate clients on various formation and governance matters, in addition to handling estate planning and probate and trust administrations. My commercial real estate practice includes property development, economic incentives and zoning matters. My residential real estate practice includes preparing real estate contracts and assisting clients throughout the closing process. I have also represented municipalities in the formation and administration of tax increment financing districts and other municipal financing mechanisms in addition to serving as general counsel on day-to-day governance matters. I received my J.D. from Northern Illinois University College of Law in 2008 and prior to that earned a B.S. degree in Criminal Justice at Illinois State University in 2005.

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not required3+ reports filed & assets ≤ $10M

Filed 3 of 4 annual reports (FY2022–FY2025)

423 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-ARApr 9, 20250001665160-25-000553
    EDGAR
  • Form C-ARMay 2, 20240001665160-24-000762
    EDGAR
  • Form C-ARApr 28, 20230001665160-23-000960
    EDGAR
  • Form C-UDec 20, 20220001665160-22-003100
    EDGAR
  • Form C/AOct 18, 20220001665160-22-002775
    EDGAR
  • Form CJul 15, 20220001665160-22-002044
    EDGAR
Source: ManualCIK 0001937683DEShare price $1.87

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.